Feasibility of Fasting & Exercise in Pts With HR+ MBC
Breast Cancer, Metastatic Breast Cancer

About this trial
This is an interventional supportive care trial for Breast Cancer focused on measuring Breast Cancer, Metastatic Breast Cancer
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of ER and/or PR+ metastatic or locally unresectable breast cancer
- Postmenopausal (including concurrent use of ovarian suppression)
Initiating endocrine therapy in combination with:
- Cohort 1: alpelisib
- Cohort 2: palbociclib
- Self-reported ability to walk two blocks
- > 18 years of age
- Approval from treating oncologist, confirmed via email or in writing
- Ability to read and understand English
Exclusion Criteria:
- Diagnosis of diabetes requiring medication
- Engaging in >90 minutes of moderate or vigorous physical activity per week
Sites / Locations
- Dana Farber Cancer Institute
Arms of the Study
Arm 1
Experimental
Prolonged Nightly Fasting Plus Exercise
Participants will be grouped into two cohorts determined by whether they receive palbociclib or alpelisib as part of their breast cancer treatment and then receive a 12 week prolonged nightly fasting plus exercise program consisting of: Prolonged overnight fasting: Not consume any calorie-containing food/drinks after 8pm, waiting a minimum of 13 hours after their last meal of the day before eating the next day, target goal of fasting at least 6 days a week, daily record of first and last meals Exercise Program: Coach provided at-home, personalized exercise regimen with target goal of 120 minutes of moderate-intensity aerobic activity each week as well as two 30-45-minute virtual strength training classes per week, receive fitbit for exercise and heart rate monitoring, weekly telephone-based support sessions with coach.